Company Showcase Oncology

Glycostem

Glycostem is a clinical-stage company, harvesting the power of allogeneic cells like Natural Killer (NK) cells – oNKord – in the field of cellular immunotherapy. Using  proprietary expansion and differentiation platform, the company can produce large amounts of effector cells from Umbilical Cord Blood stem cells. Products are composed of high-quality, pure and active cells. NK cells have the capability to control viral infections, target cancer and kill senescent cells. 

NK cells have the capability to control viral infections, target cancer and kill senescent cells. Unfortunately, our immune system can be compromised, allowing tumor cells to escape the immunological control mechanisms. Allogeneic conditions will be able to mitigate this problem. Glycostem’s concept and product pipeline is based on this principle.Recently, the lead product – oNKord® – has been tested for safety and efficacy in a phase I study with Acute Myeloid Leukemia (AML) patients. oNKord® showed no toxicity, expanded in vivo, migrated to the bone marrow and killed leukemic blasts.

Glycostem是一家处于临床阶段的公司,在细胞免疫疗法领域中,它收集了诸如自然杀伤(NK)细胞(oNKord)等同种异体细胞的功能。 使用专有的扩增和分化平台,该公司可以从脐带血干细胞生产大量效应细胞。 产品由高质量,纯净和活跃的细胞组成。NK细胞具有控制病毒感染,靶向癌症和杀死衰老细胞的能力。

NK细胞具有控制病毒感染,靶向癌症和杀死衰老细胞的能力。 不幸的是,我们的免疫系统可能受到损害,使肿瘤细胞逃脱了免疫控制机制。 异基因条件将能够减轻这个问题。 Glycostem的概念和产品线就是基于这一原理。最近,在针对急性髓样白血病(AML)患者的I期研究中,主导产品oNKord®已通过安全性和有效性测试, oNKord®没有毒性,可以在体内扩增,可以迁移到骨髓并杀死白血病细胞。

%d bloggers like this: